Proteasome Inhibitors in Cancer Therapy

  • Julian Adams

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xv
  2. Cancer Drug Development

    1. Front Matter
      Pages 1-1
    2. Barry Greene, Michael Kauffman
      Pages 3-13
  3. Chemistry and Cell Biology of the Proteasome

    1. Front Matter
      Pages 15-15
    2. Alfred L. Goldberg
      Pages 17-38
    3. Kyung Bo Kim, Craig M. Crews
      Pages 47-63
    4. Carlos García-Echeverría
      Pages 65-75
    5. Julian Adams
      Pages 77-84
    6. Simon A. Williams, David J. McConkey
      Pages 85-98
    7. Susan L. Holbeck, Edward A. Sausville
      Pages 99-107
  4. Rationale for Proteasome Inhibitors in Cancer

    1. Front Matter
      Pages 109-109
    2. Frank Pajonk, William H. McBride
      Pages 111-121
    3. Carter Van Waes, John B. Sunwoo, William DeGraff, James B. Mitchell
      Pages 123-130
    4. James C. Cusack Jr.
      Pages 131-143
    5. Leonard Liebes, Bruce Ng, Yi-He Ling, Roman Perez-Soler
      Pages 145-159
    6. Jeffrey J. Olson, Geoffrey Bowers, Zhoabin Zhang
      Pages 161-170
    7. Robert Z. Orlowski
      Pages 171-180
    8. Thomas J. Sayers
      Pages 181-191
    9. Edward G. Mimnaugh, Leonard M. Neckers
      Pages 193-205
    10. Marcus Groettrup, Rita de Giuli, Gunter Schmidtke
      Pages 207-216
  5. Clinical Trials

    1. Front Matter
      Pages 231-231
    2. Julian Adams, Peter J. Elliott, Page Bouchard
      Pages 233-269
    3. Dixie-Lee W. Esseltine, David P. Schenkein
      Pages 271-282
    4. Jeffrey S. Ross, Gerald P. Linette, Geoffrey S. Ginsburg, William Trepicchio, Oscar Kashala, Rebecca Mosher et al.
      Pages 283-299
  6. Back Matter
    Pages 307-313

About this book


Immediately upon the discovery some ten years ago that inhibition of the proteasome in cultured cells, mostly of tumor origin, caused the programmed cell death machinery to ramp up, it became imperative to investigate proteasome inhibition as a possible treatment for human cancers. In Proteasome Inhibitors in Cancer Therapy, Julian Adams, the leader in developing the field, brings together a panel of highly experienced academic and pharmaceutical investigators to take stock of the remarkable work that has been accomplished to date, and examine emerging therapeutic possibilities for proteasome inhibitors in cancer. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of the very empirical and practical development of rationales to test proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of proteasome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (Velcade™) through multicentered clinical trials in patients with relapsed and refractory myeloma to FDA approval, and describe how modern pharmacogenomic tools can be used to predict which patients will respond to such proteasome inhibitor therapy. Additional chapters on the proteasome's basic biochemistry review its mechanism in the cell cycle and apoptosis and suggest opportunities for using proteasome inhibitors to find additional medicinal targets.
Authoritative and illuminating, Proteasome Inhibitors in Cancer Therapy makes clear that proteasome inhibition should prove a fertile area for the many future discoveries that will provide relief of suffering and extend the quality of life of patients afflicted with cancer and other debilitating diseases.


AIDS Antigen Chemotherapie apoptosis diagnostics

Editors and affiliations

  • Julian Adams
    • 1
  1. 1.Infinity Pharmaceuticals Inc.CambridgeUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology